Mrs Jennifer Down

All publications

Journal articles

• Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.. Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
• Griffin J, Down J, Quayle LA, Heath PR, Gibb EA, Davicioni E, Liu Y, Zhao X, Swain J, Wang D , Hussain S et al (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10(2). View this article in WRRO
• Zhou J, Down JM, George CN, Murphy J, Lefley DV, Tulotta C, Alsharif MA, Leach M & Ottewell PD (2022) Novel methods of targeting IL-1 signalling for the treatment of breast cancer bone metastasis. Cancers, 14(19).
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al (2021) The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties. Journal of Bone Oncology, 31. View this article in WRRO
• Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
• Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A , Rajalingam K et al (2020) The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. View this article in WRRO
• Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research, 34(12), 2311-2326. View this article in WRRO
• Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
• Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2018) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
• Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6). View this article in WRRO
• (2018) CORRIGENDUM FOR “Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development”. Endocrinology, 159(4), 1762-1762.
• Chai RC, McDonald MM, Terry RL, Kovačić N, Down JM, Pettitt JA, Mohanty ST, Shah S, Haffari G, Xu J , Gillespie MT et al (2017) Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget, 8, 68047-68058. View this article in WRRO
• Chinnaiya K, Lawson MA, Thomas S, Haider M-T, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339. View this article in WRRO
• Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA , Neil Dear T et al (2015) Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 6(1), ---. View this article in WRRO
• Bassett JHD, van der Spek A, Logan JG, Gogakos A, Bagchi-Chakraborty J, Murphy E, van Zeijl C, Down J, Croucher PI, Boyde A , Boelen A et al (2015) Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development. Endocrinology, 156(9), 3098-3113.
• Reeves KJ, Hurrell JE, Cecchini M, van der Pluijm G, Down JM, Eaton CL, Hamdy F, Clement-Lacroix P & Brown NJ (2015) Prostate cancer cells home to bone using a novelin vivomodel: Modulation by the integrin antagonist GLPG0187. International Journal of Cancer, 136(7), 1731-1740.
• Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B , McKenna CE et al (2015) Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer. Cancer Discovery, 5(1), 35-42.
• Mathew G, Mitchell A, Down JM, Jacobs LA, Hamdy FC, Eaton C, Rosario DJ, Cross SS & Winder SJ (2013) Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Scientific Reports, 3(1). View this article in WRRO
• Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, Pesce G, Phillips JT, Yen OS, Thalmann GN , Wright PC et al (2012) iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer.. PLoS ONE. View this article in WRRO
• van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG , Pelger RCM et al (2010) High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer Research, 70(12), 5163-5173.
• Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F & Thalman G (2010) Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. The Prostate, 70(8), 875-882.
• Glen A, Evans CA, Gan CS, Cross SS, Hamdy FC, Gibbins J, Lippitt J, Eaton CL, Noirel J, Wright PC & Rehman I (2010) Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. The Prostate, n/a-n/a.
• Cross SS, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian SP, Reed MW, Eaton C, Catto JW, Hamdy F & Winder SJ (2008) Expression of beta-dystroglycan is reduced or absent in many human carcinomas.. Histopathology, 53(5), 561-566.
• Waterman EA, Cross NA, Lippitt JM, Cross SS, Rehman I, Holen I, Hamdy FC & Eaton CL (2007) The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers. International Journal of Cancer, 121(9), 1958-1966.
• Cross SS (2006) Expression of receptor activator of nuclear factor    ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. Journal of Clinical Pathology, 59(7), 716-720.
• Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) Osteoprotegerin (OPG)-a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?. International Journal of Cancer, 118(8), 1901-1908.
• Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?. Breast Cancer Research and Treatment, 92(3), 207-215.
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ & Carding SR (2003) Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity, 19(6), 849-861.
• Shipman CM, Vanderkerken K, De Raeve H, Perry M, Hijzen A, Lippitt J, Green J, Van Marck E, Van Camp B & Croucher PI (2002) Zoledronic acid prevents the development of myeloma bone disease and increases survival. JOURNAL OF BONE AND MINERAL RESEARCH, 17(7), 1328-1328.
• Croucher P, De Raeve H, Perry M, Hijzen A, Shipman C, Lippitt J, Green J, Van Marck E, Van Camp B & Vanderkerken K (2002) Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. BONE, 30(3), 39S-39S.
• Shipman CM, Lippitt JM & Croucher PI (2002) Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?. BONE, 30(3), 32S-32S.
• Ashcroft AJ, Lippitt JM, Perry MJ, Rollinson SJ, Croucher PI, Carding SR & Morgan GJ (2001) Interleukin 2 deficiency induces bone destruction associated with dysregulation of the rank/rank ligand/osteoprotegerin system. Blood, 98(11 PART I).
• Croucher PI, Hijzen A, Shipman CM, Perry M, Lippitt J, Green J, Van Camp B & Vanderkerken K (2001) Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood, 98(11 PART I).
• Croucher PI, Shipman CM, Perry M, Lippitt J, Asosingh K, van Beek EJR, Van Camp B, Russell RGG, Dunstan C & Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. BONE, 28(5), S81-S81.
• Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I & Skerry TM (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98(13), 3534-3540.
• Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Russell RGG & Croucher PI (2000) The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. British Journal of Haematology, 111(1), 283-286.
• Shipman CM, Holen I, Lippitt JM, Vandenberghe E & Croucher PI (2000) Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. BLOOD, 96(11), 360A-360A.
• Croucher PI, Shipman CM, Perry MJ, Lippitt J, Asosingh K, van Beek EJR, Van Camp B, Russell GG, Dunstan C & Vanderkerken K (2000) Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.. BLOOD, 96(11), 761A-761A.
• Shipman CM, Holen I, Lippitt JM, Edwards T & Croucher PI (2000) Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. JOURNAL OF BONE AND MINERAL RESEARCH, 15(6), 1217-1217.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al () Targeting the Tumour Antigen 5T4 using CAR-T Cells for the Treatment of Acute Myeloid Leukaemia. Molecular Cancer Therapeutics.
• Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, Pesce G, Phillips JT, Ow SY, Thalmann GN , Wright PC et al () Correction: iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer. PLoS ONE, 7(5).
• Crawford A, Frazer A, Lippitt JM, Buttle DJ & Smith T () A case of chondromatosis indicates a synovial stem cell aetiology. Rheumatology, 45(12), 1529-1533.
• Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC & Eaton CL () Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis. Journal of Bone and Mineral Research, 19(10), 1712-1721.
• Croucher PI, De Raeve H, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B & Vanderkerken K () Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival. Journal of Bone and Mineral Research, 18(3), 482-492.

Conference proceedings papers

• Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
• Griffin J, Down J, Quayle L, Heath P & Catto J (2023) Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial. JOURNAL OF PATHOLOGY, Vol. 261(SUPPL1) (pp S49-S49)
• Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
• Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018. View this article in WRRO
• Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) TARGETING FREE LIGHT CHAIN (FLC) SECRETION AND THE UNFOLDED PROTEIN RESPONSE IN MYELOMA CELLS USING VAN, A COMBINATION OF REPURPOSED DRUGS. EXPERIMENTAL HEMATOLOGY, Vol. 64 (pp S75-S75)
• Pesce* G, Glen A, Lippitt J, Fowles A, Rehman I & Eaton CL (2011) Spontaneous fusion between prostate cancer cells: A driver for development of tumor heterogeneity and growth in bone. Bone, Vol. 48(1) (pp S46-S47)
• Cross NA, Papageorgiou M, Lippitt J, Nyambo R, Hamdy FC & Eaton CL (2007) Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A94-A94)
• Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
• Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
• Cross SS, Hollingbury FE, Lippitt JM, Evans CA, Balasubramanian SP, Reed MWR, Handy FC & Winder SJ (2005) Loss of intercellular expression of beta-dystroglycan is a common event in breast cancer. JOURNAL OF PATHOLOGY, Vol. 205 (pp 8-8)
• Cross SS, Hollingbury FE, Lippitt JM, Feeley KM, Azzouzi AR, Winder SJ & Hamdy FC (2005) Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation. JOURNAL OF PATHOLOGY, Vol. 205 (pp 15-15)
• Cross SS, Hollingbury FE, Lippitt JM, Catto JW, Hamdy EC & Winder SJ (2005) beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6)
• Papageorgiou M, Lippitt J, Nyambo R, Cross N, Hamdy FC & Eaton CL (2005) Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan CR, Carding SR & Morgan GJ (2004) T-cell-mediated colitis and bone destruction in a murine model of autoimmunity are both driven by RANK/RANK LIGAND interactions and modulated by recombinant Fc-OPG. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 67-67)
• Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Lippitt JM, Child JA, Dunstan C, Carding SR & Morgan GM (2003) T cell mediated colitis and bone destruction are driven by RANK/RANK LIGAND interactions and can be modulated by recombinant Fc-OPG.. BLOOD, Vol. 102(11) (pp 528A-528A)
• Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376)
• Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17(7) (pp 1339-1339)
• Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)

Other

• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Table 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Table 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Figure 4 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Figure 3 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Figure 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Supplementary Figure 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al (2025) Data from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.

Preprints

• Jiang Y, Down JM, Maynard S, Jenkins S, Ferritti L, Beke F, Al-Hazmi B, Southam AD, Kvist J, Mirbahai L , Besse L et al (2023) A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM), Research Square Platform LLC.
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al () The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties, Cold Spring Harbor Laboratory.